AWP
BMRN icon

Abacus Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Abacus Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,297
Closed -$356K – 349
2026
Q1 		$356K Buy
6,297
+2,409
+62% +$140K 0.03% 305
2025
Q4 		$231K Buy
+3,888
New +$212K 0.02% 433

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Abacus Wealth Partners's BMRN Position: Q2 2026 in Review

Abacus Wealth Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 6,297 shares — an estimated $356K sold.

Abacus Wealth Partners first reported a position in BMRN in Q4 2025 and held it in 2 quarters. The position peaked at $356K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Abacus Wealth Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Abacus Wealth Partners sold 6,297 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $356K.
  • Abacus Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Abacus Wealth Partners's BioMarin Pharmaceuticals position peaked at $356K in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Abacus Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.